Latigo Biotherapeutics, Inc.

LTGO Nasdaq SEC CIK 2056611
Follow Latigo Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$20.9M +15.5% vs same quarter last year
EPS, diluted −$0.55 +98.1% vs same quarter last year
Operating cash flow −$19.5M +2% vs same quarter last year
Operating income −$22.9M +7.3% vs same quarter last year
Net income by quarter
−$21M
−$25.8M
−$24.8M
−$23M
−$25.8M
−$20.9M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing